0001209191-22-042841.txt : 20220721
0001209191-22-042841.hdr.sgml : 20220721
20220721160548
ACCESSION NUMBER: 0001209191-22-042841
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220720
FILED AS OF DATE: 20220721
DATE AS OF CHANGE: 20220721
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chacko Jacob
CENTRAL INDEX KEY: 0001608936
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39269
FILM NUMBER: 221097119
MAIL ADDRESS:
STREET 1: C/O IGNYTA, INC.
STREET 2: 11095 FLINTKOTE AVE., SUITE D
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001796280
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 471787157
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 E. GRAND AVE.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 388-5600
MAIL ADDRESS:
STREET 1: 240 E. GRAND AVE.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-20
0
0001796280
Oric Pharmaceuticals, Inc.
ORIC
0001608936
Chacko Jacob
C/O ORIC PHARMACEUTICALS, INC.
240 E. GRAND AVE., 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Stock Option (right to buy)
16.00
2022-07-20
4
D
0
437500
D
2030-04-22
Common Stock
437500
0
D
Stock Option (right to buy)
29.83
2022-07-20
4
D
0
280000
D
2031-01-31
Common Stock
280000
0
D
Stock Option (right to buy)
9.48
2022-07-20
4
D
0
300000
D
2032-01-31
Common Stock
300000
0
D
Stock Option (right to buy)
4.36
2022-07-20
4
A
0
437500
A
2032-07-19
Common Stock
437500
437500
D
Stock Option (right to buy)
4.36
2022-07-20
4
A
0
280000
A
2032-07-19
Common Stock
280000
280000
D
Stock Option (right to buy)
4.36
2022-07-20
4
A
0
300000
A
2031-07-19
Common Stock
300000
300000
D
Twenty five percent (25%) of the shares subject to the option vested on April 23, 2021, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter.
On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share.
Twenty five percent (25%) of the shares subject to the option vested on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested each month thereafter.
Twenty five percent (25%) of the shares subject to the option would have vested on February 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option would have vested each month thereafter.
One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter.
Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
/s/ Christian Kuhlen, attorney-in-fact
2022-07-21